Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung CancerJ. Clin. Oncol 2021 Jan 15;[EPub Ahead of Print], H Borghaei, S Gettinger, EE Vokes, LQM Chow, MA Burgio, J de Castro Carpeno, A Pluzanski, O Arrieta, OA Frontera, R Chiari, C Butts, J Wójcik-Tomaszewska, B Coudert, MC Garassino, N Ready, E Felip, MA García, D Waterhouse, M Domine, F Barlesi, S Antonia, M Wohlleber, DE Gerber, G Czyzewicz, DR Spigel, L Crino, WEE Eberhardt, A Li, S Marimuthu, J Brahmer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.